Literature DB >> 22504376

Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?

Tetsuhide Ito, Hisato Igarashi, Robert T Jensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22504376      PMCID： PMC3335441          DOI： 10.1097/MPA.0b013e318249a92a

Source DB:  PubMed          Journal:  Pancreas        ISSN： 0885-3177            Impact factor:   3.327


× No keyword cloud information.
  21 in total

Review 1.  Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.

Authors:  Robert T Jensen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-01       Impact factor: 4.080

Review 2.  Granins and granin-related peptides in neuroendocrine tumours.

Authors:  Guida M Portela-Gomes; Lars Grimelius; Erik Wilander; Mats Stridsberg
Journal:  Regul Pept       Date:  2010-03-06

Review 3.  Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.

Authors:  Irvin M Modlin; Bjorn I Gustafsson; Steven F Moss; Marianne Pavel; Apostolos V Tsolakis; Mark Kidd
Journal:  Ann Surg Oncol       Date:  2010-03-09       Impact factor: 5.344

4.  Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies.

Authors:  Andreas Tartaglia; Guida M Portela-Gomes; Kjell Oberg; Paolo Vezzadini; Maria P Foschini; Mats Stridsberg
Journal:  Virchows Arch       Date:  2006-01-12       Impact factor: 4.064

5.  Prohormone convertase-1 is essential for conversion of chromogranin A to pancreastatin.

Authors:  V Udupi; H M Lee; A Kurosky; G H Greeley
Journal:  Regul Pept       Date:  1999-09-15

6.  Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior.

Authors:  Thomas M O'Dorisio; Siegfried R Krutzik; Eugene A Woltering; Erika Lindholm; Saju Joseph; Abby E Gandolfi; Yi-Zarn Wang; J Phillip Boudreaux; Aaron I Vinik; Vay Liang W Go; James R Howe; Thor Halfdanarson; M Sue O'Dorisio; Gregg Mamikunian
Journal:  Pancreas       Date:  2010-07       Impact factor: 3.327

Review 7.  The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties.

Authors:  K B Helle; A Corti; M H Metz-Boutigue; B Tota
Journal:  Cell Mol Life Sci       Date:  2007-11       Impact factor: 9.261

8.  Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients.

Authors:  U Syversen; M Mignon; S Bonfils; A Kristensen; H L Waldum
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

9.  A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours.

Authors:  R L Stronge; G B Turner; B T Johnston; D R McCance; A McGinty; C C Patterson; J E S Ardill
Journal:  Ann Clin Biochem       Date:  2008-09-09       Impact factor: 2.057

10.  Isolation and primary structure of tumor-derived peptides related to human pancreastatin and chromogranin A.

Authors:  W E Schmidt; E G Siegel; H Kratzin; W Creutzfeldt
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205
View more
  15 in total

1.  Pancreastatin predicts survival in neuroendocrine tumors.

Authors:  Scott K Sherman; Jessica E Maxwell; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Ann Surg Oncol       Date:  2014-04-22       Impact factor: 5.344

Review 2.  Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.

Authors:  Tetsuhide Ito; Guillaume Cadiot; Robert T Jensen
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

Review 3.  Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.

Authors:  Tetsuhide Ito; Susumu Hijioka; Toshihiko Masui; Atsuko Kasajima; Yuji Nakamoto; Noritoshi Kobayashi; Izumi Komoto; Masayuki Hijioka; Lingaku Lee; Hisato Igarashi; Robert Thomas Jensen; Masayuki Imamura
Journal:  J Gastroenterol       Date:  2016-08-18       Impact factor: 7.527

4.  Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.

Authors:  Pari Shah; Maneesh H Singh; Yu-Xiao Yang; David C Metz
Journal:  Pancreas       Date:  2013-08       Impact factor: 3.327

Review 5.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

6.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

Review 7.  Pharmacotherapy of Zollinger-Ellison syndrome.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2013-01-30       Impact factor: 3.889

8.  Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.

Authors:  Wei Qiu; Ioannis Christakis; Angelica Silva; Roland L Bassett; Liyun Cao; Qing H Meng; Elizabeth Gardner Grubbs; Hua Zhao; James C Yao; Jeffrey E Lee; Nancy D Perrier
Journal:  Clin Endocrinol (Oxf)       Date:  2016-06-30       Impact factor: 3.478

Review 9.  Biochemical Testing in Neuroendocrine Tumors.

Authors:  Vidya Aluri; Joseph S Dillon
Journal:  Endocrinol Metab Clin North Am       Date:  2017-06-12       Impact factor: 4.741

10.  Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.

Authors:  Masami Miki; Tetsuhide Ito; Masayuki Hijioka; Lingaku Lee; Kohei Yasunaga; Keijiro Ueda; Takashi Fujiyama; Yuichi Tachibana; Ken Kawabe; Robert T Jensen; Yoshihiro Ogawa
Journal:  Jpn J Clin Oncol       Date:  2017-06-01       Impact factor: 3.019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.